Associated Papers
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.
Thorvaldsdottir B et al.
Leukemia, 2025
40275070 (PubMed )
Supplement: 41375_2025_2615_MOESM2_ESM.xlsx › Supplemental_Table_S3
Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy.
Jóri B et al.
Cancers, 2021
34201252 (PubMed )
Supplement: cancers-13-02861-s001.zip › cancers-1214406-supplementary.pdf
Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors.
Yamamoto K et al.
Elife, 2016
27304073 (PubMed )
Supplement: elife-14709-supp1.xlsx › Supplementary_Information_1B
Select a paper to view details